Latest stories on AXSM
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’
Stocktwits News63 · neutralanalyst
Axsome rises on Auvelity prescription data
Seeking Alpha67 · bullishproduct/pr
Axsome rises as Mizuho highlights ‘big month-over-month jump’ for Auvelity
The Fly63 · neutralanalyst
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool53 · neutralanalyst
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Axsome pullback brings attractive entry point, says H.C. Wainwright
The Fly56 · neutralanalyst
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Business Insider63 · neutralproduct/pr
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Finance57 · neutralanalyst
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool57 · neutralanalyst
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Yahoo Top67 · bullishgeneral
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
The Motley Fool67 · bullishgeneral
Mizuho raises Axsome Therapeutics stock price target on Auvelity
Investing.com Analyst Ratings61 · neutralanalyst
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
Seeking Alpha32 · bearishearnings
RBC cuts Axsome Therapeutics stock price target on model updates
Investing.com Analyst Ratings38 · neutralanalyst
Axsome Therapeutics Price Target Lowered To 297 From 304 At Rbc Capital
The Fly42 · neutralanalyst
Axsome Therapeutics Price Target Raised To 251 From 242 At Morgan Stanley
The Fly61 · neutralanalyst
Guggenheim raises Axsome Therapeutics stock price target on sales beat
Investing.com Analyst Ratings61 · neutralanalyst
Axsome Therapeutics price target raised to $275 from $260 at Guggenheim
The Fly61 · neutralanalyst
Axsome Therapeutics Price Target Raised To 256 From 255 At Wells Fargo
The Fly61 · neutralanalyst
Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
AXSM Stock Advances on CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030
Stocktwits News63 · neutralproduct/pr